The AHEAD-MERIT trial will take place in 15 hospitals, targeting patients with aggressive HPV-associated cancers with an innovative vaccine.
Gabriel Dumitrache
International
Foto: Shutterstock
Always see our news on Google
The AHEAD-MERIT clinical trial will take place in 15 hospitals in England, targeting patients with aggressive human papillomavirus (HPV)-associated cancers. These cancers have high rates of recurrence and poor survival. The vaccine being developed targets proteins commonly found in HPV-associated head and neck cancer. The health secretary declared the initiative a "huge victory" and NHS England is working with BioNTech to identify eligible patients. This is the third trial under the NHS Cancer Vaccine Launch Pad, which has already supported 550 patients.
Sources
Latest News
21:47
Germany has reported approximately 14,000 deaths associated with the heatwave this summer.
21:33
Mihai Dimian, the Minister of Education, about cutting scholarships for students on vacation: "We confuse the scholarship with the allowance"
21:17
The Minister of Education has denied rumors regarding the lack of surveillance cameras and the elimination of anonymization of papers in the admission exams.
21:07
Starting tomorrow, the Basarab Passage will reopen in the Titulescu-Grozăvești direction. The passage will fully reopen on September 7.
20:41
Petrișor Peiu rejects the accusations that the Opposition voted for the purchase of gas from the Neptun Deep field at too high a price.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
